#United States #New York #Armata Pharmaceuticals #Investment Conference #bacteriophage

Armata Pharmaceuticals to Participate in H.C. Wainwright Conference

Armata Pharmaceuticals, Inc., a leading name in advanced biotechnology, is set to showcase its innovative research at the H.C. Wainwright 28th Annual Global Investment Conference.

Scheduled for September 14-16, 2026, in New York, this conference is a key event for investors interested in the latest developments in biotechnology and pharmaceutical industries. Armata’s CEO, Deborah Birx, M.D., will present on September 16 from 11:00 to 11:30 AM EDT, highlighting the company’s high-purity, pathogen-specific bacteriophage therapeutics, which offer promising solutions for antibiotic-resistant and challenging bacterial infections.

Armata Pharmaceuticals is at the forefront of developing bacteriophage-based therapies. These therapies represent a new hope in treating bacterial infections that are proving difficult to tackle with conventional antibiotics. The company’s work focuses on creating high-purity bacteriophages—viruses that specifically target and attack bacteria—making them effective alternatives in antibiotic-resistant scenarios.

Breakthrough Technologies

Armata utilizes its proprietary technology to develop a robust pipeline of bacteriophage candidates. Among these candidates are several that are now in clinical development targeting significant pathogens including Pseudomonas aeruginosa and Staphylococcus aureus. The comprehensive approach taken by Armata spans from laboratory bench to clinical application, ensuring that their products are not just theoretical but practically viable for patient care.

The use of bacteriophage therapy is gaining traction in the field as traditional antibiotics face rising resistance rates. The implications of Armata's research could revolutionize the way bacterial infections are treated, possibly saving countless lives while overcoming the challenges presented by antibiotic resistance.

Meeting Opportunities

The conference will feature opportunities for one-on-one meetings, allowing investors and partners to engage directly with Armata's leadership. Those interested in scheduling a meeting can reach out to their H.C. Wainwright representatives for arrangements.

Commitment to Phage Therapy

Armata is dedicated to advancing its pipeline of phage therapies, which are designed to be both effective and safe for patients. The company boasts in-house capabilities for cGMP (current Good Manufacturing Practice) manufacturing of its bacteriophage products, vital for supporting the eventual commercialization of their therapies. This comprehensive manufacturing approach not only complies with regulatory requirements but also ensures the highest standards of product quality.

As Armata Pharmaceuticals prepares for this significant event, its participation in the H.C. Wainwright conference is a clear indication of the company's commitment to addressing one of the most pressing issues in modern medicine—treating infections that resist present-day antibiotic treatments. Investors keen on innovative solutions in healthcare will undoubtedly find Armata's presentation a highlight of this year’s conference.